Optiver Holding
NPCE icon

Optiver Holding’s Neuropace NPCE Stock Holding History

Optiver Holding’s Portfolio NPCE Stock Details NPCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.34K Sell
254
-16
-6% -$240 ﹤0.01% 1607
2025
Q4 		$4.17K Sell
270
-162
-38% -$2.17K ﹤0.01% 1502
2025
Q3 		$4.45K Buy
+432
New +$4.07K ﹤0.01% 1842

Other funds holding NPCE

PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Optiver Holding's NPCE Position: Q1 2026 in Review

Optiver Holding reduced its Neuropace (NPCE) stake by 5.9% in Q1 2026, selling an estimated $240 and leaving 254 shares worth $3.34K. The position accounts for ﹤0.01% of the portfolio, ranked #1607.

Optiver Holding first reported a position in NPCE in Q3 2025 and has held it in 3 quarters since. The position peaked at $4.45K in Q3 2025. 113 funds tracked by Wall St. Rank hold NPCE as of Q1 2026.

  • Optiver Holding held 254 shares of Neuropace worth $3.34K as of Q1 2026.
  • Optiver Holding sold 16 Neuropace shares in Q1 2026, an estimated $240.
  • Neuropace made up ﹤0.01% of Optiver Holding's portfolio in Q1 2026, its #1607 holding.
  • Optiver Holding first reported a position in Neuropace in Q3 2025 and has held it in 3 quarters since.
  • Optiver Holding's Neuropace position peaked at $4.45K in Q3 2025.
  • 113 funds tracked by Wall St. Rank held Neuropace as of Q1 2026.

Based on Optiver Holding's 13F filing for Q1 2026, filed 15 May 2026.